Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro

Song Kao-Shan Chien Song Kao-Shan, K. Micetich, L. A. Zwelling, J. Whang-Peng

研究成果: 雜誌貢獻文章

14 引文 (Scopus)

摘要

Amsacrine (m-AMSA) is presently being utilized in phase I-II studies at the Medicine Branch, National Cancer Institute, National Institutes of Health (Bethesda, MD), and is being administered as a continuous infusion to patients with progressive malignancy after conventional therapy. In the present study, we examined the effects of this drug, in vivo and in vitro, on chromosomal morphology and the frequency of sister chromatid exchange (SCE) induction in human peripheral blood lymphocytes. In the in vivo studies, eight patients receiving 30 mg/m2/day of m-AMSA by continuous infusion showed increased levels of chromosomal aberrations, up to a maximum of 14% (median; range, 10%-24%) at 96 hours compared to 1% (median; range, 0%-4%) in the control group; no increase was noted in SCE frequencies. In vitro studies of normal human lymphocytes with various concentrations of m-AMSA, including doses comparable to those used in vivo, showed both increased levels of chromosomal aberrations, ranging from 8% to 100%, and increased SCEs, ranging from 1.5 times the normal at the lowest concentration studied (0.005 μg/ml) to 12 times the normal (0.25 μg/ml). In correlating SCEs with breaks in the in vitro studies, it was found that two-thirds of the total breaks occurred at SCE points; this indicates a close relationship between the events leading to these two types of aberrations. In vitro isotope incorporation studies showed inhibition of both RNA and DNA synthesis but no significant inhibition of synthesis; at a dose of 5.0 μg/ml, RNA synthesis was 80% inhibited and DNA synthesis was 60% inhibited after 36 hours of incubation with m-AMSA. The difference in the results between in vitro and in vivo SCE studies may be due to possible DNA repair in the in vivo-treated lymphocytes in m-AMSA-free medium in vitro, a process not available to the in vitro-treated cells.
原文英語
頁(從 - 到)989-997
頁數9
期刊Cancer Treatment Reports
68
發行號7-8
出版狀態已發佈 - 一月 1 1984
對外發佈Yes

指紋

Amsacrine
Cytogenetics
Lymphocytes
Sister Chromatid Exchange
Chromosome Aberrations
RNA
National Cancer Institute (U.S.)
DNA
National Institutes of Health (U.S.)
In Vitro Techniques
Isotopes
DNA Repair
Medicine
Control Groups

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

引用此文

Chien Song Kao-Shan, S. K-S., Micetich, K., Zwelling, L. A., & Whang-Peng, J. (1984). Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. Cancer Treatment Reports, 68(7-8), 989-997.

Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. / Chien Song Kao-Shan, Song Kao-Shan; Micetich, K.; Zwelling, L. A.; Whang-Peng, J.

於: Cancer Treatment Reports, 卷 68, 編號 7-8, 01.01.1984, p. 989-997.

研究成果: 雜誌貢獻文章

Chien Song Kao-Shan, SK-S, Micetich, K, Zwelling, LA & Whang-Peng, J 1984, 'Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro', Cancer Treatment Reports, 卷 68, 編號 7-8, 頁 989-997.
Chien Song Kao-Shan SK-S, Micetich K, Zwelling LA, Whang-Peng J. Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. Cancer Treatment Reports. 1984 1月 1;68(7-8):989-997.
Chien Song Kao-Shan, Song Kao-Shan ; Micetich, K. ; Zwelling, L. A. ; Whang-Peng, J. / Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. 於: Cancer Treatment Reports. 1984 ; 卷 68, 編號 7-8. 頁 989-997.
@article{92b4930d40cc4d6582f3574983e93077,
title = "Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro",
abstract = "Amsacrine (m-AMSA) is presently being utilized in phase I-II studies at the Medicine Branch, National Cancer Institute, National Institutes of Health (Bethesda, MD), and is being administered as a continuous infusion to patients with progressive malignancy after conventional therapy. In the present study, we examined the effects of this drug, in vivo and in vitro, on chromosomal morphology and the frequency of sister chromatid exchange (SCE) induction in human peripheral blood lymphocytes. In the in vivo studies, eight patients receiving 30 mg/m2/day of m-AMSA by continuous infusion showed increased levels of chromosomal aberrations, up to a maximum of 14{\%} (median; range, 10{\%}-24{\%}) at 96 hours compared to 1{\%} (median; range, 0{\%}-4{\%}) in the control group; no increase was noted in SCE frequencies. In vitro studies of normal human lymphocytes with various concentrations of m-AMSA, including doses comparable to those used in vivo, showed both increased levels of chromosomal aberrations, ranging from 8{\%} to 100{\%}, and increased SCEs, ranging from 1.5 times the normal at the lowest concentration studied (0.005 μg/ml) to 12 times the normal (0.25 μg/ml). In correlating SCEs with breaks in the in vitro studies, it was found that two-thirds of the total breaks occurred at SCE points; this indicates a close relationship between the events leading to these two types of aberrations. In vitro isotope incorporation studies showed inhibition of both RNA and DNA synthesis but no significant inhibition of synthesis; at a dose of 5.0 μg/ml, RNA synthesis was 80{\%} inhibited and DNA synthesis was 60{\%} inhibited after 36 hours of incubation with m-AMSA. The difference in the results between in vitro and in vivo SCE studies may be due to possible DNA repair in the in vivo-treated lymphocytes in m-AMSA-free medium in vitro, a process not available to the in vitro-treated cells.",
author = "{Chien Song Kao-Shan}, {Song Kao-Shan} and K. Micetich and Zwelling, {L. A.} and J. Whang-Peng",
year = "1984",
month = "1",
day = "1",
language = "English",
volume = "68",
pages = "989--997",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7-8",

}

TY - JOUR

T1 - Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro

AU - Chien Song Kao-Shan, Song Kao-Shan

AU - Micetich, K.

AU - Zwelling, L. A.

AU - Whang-Peng, J.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - Amsacrine (m-AMSA) is presently being utilized in phase I-II studies at the Medicine Branch, National Cancer Institute, National Institutes of Health (Bethesda, MD), and is being administered as a continuous infusion to patients with progressive malignancy after conventional therapy. In the present study, we examined the effects of this drug, in vivo and in vitro, on chromosomal morphology and the frequency of sister chromatid exchange (SCE) induction in human peripheral blood lymphocytes. In the in vivo studies, eight patients receiving 30 mg/m2/day of m-AMSA by continuous infusion showed increased levels of chromosomal aberrations, up to a maximum of 14% (median; range, 10%-24%) at 96 hours compared to 1% (median; range, 0%-4%) in the control group; no increase was noted in SCE frequencies. In vitro studies of normal human lymphocytes with various concentrations of m-AMSA, including doses comparable to those used in vivo, showed both increased levels of chromosomal aberrations, ranging from 8% to 100%, and increased SCEs, ranging from 1.5 times the normal at the lowest concentration studied (0.005 μg/ml) to 12 times the normal (0.25 μg/ml). In correlating SCEs with breaks in the in vitro studies, it was found that two-thirds of the total breaks occurred at SCE points; this indicates a close relationship between the events leading to these two types of aberrations. In vitro isotope incorporation studies showed inhibition of both RNA and DNA synthesis but no significant inhibition of synthesis; at a dose of 5.0 μg/ml, RNA synthesis was 80% inhibited and DNA synthesis was 60% inhibited after 36 hours of incubation with m-AMSA. The difference in the results between in vitro and in vivo SCE studies may be due to possible DNA repair in the in vivo-treated lymphocytes in m-AMSA-free medium in vitro, a process not available to the in vitro-treated cells.

AB - Amsacrine (m-AMSA) is presently being utilized in phase I-II studies at the Medicine Branch, National Cancer Institute, National Institutes of Health (Bethesda, MD), and is being administered as a continuous infusion to patients with progressive malignancy after conventional therapy. In the present study, we examined the effects of this drug, in vivo and in vitro, on chromosomal morphology and the frequency of sister chromatid exchange (SCE) induction in human peripheral blood lymphocytes. In the in vivo studies, eight patients receiving 30 mg/m2/day of m-AMSA by continuous infusion showed increased levels of chromosomal aberrations, up to a maximum of 14% (median; range, 10%-24%) at 96 hours compared to 1% (median; range, 0%-4%) in the control group; no increase was noted in SCE frequencies. In vitro studies of normal human lymphocytes with various concentrations of m-AMSA, including doses comparable to those used in vivo, showed both increased levels of chromosomal aberrations, ranging from 8% to 100%, and increased SCEs, ranging from 1.5 times the normal at the lowest concentration studied (0.005 μg/ml) to 12 times the normal (0.25 μg/ml). In correlating SCEs with breaks in the in vitro studies, it was found that two-thirds of the total breaks occurred at SCE points; this indicates a close relationship between the events leading to these two types of aberrations. In vitro isotope incorporation studies showed inhibition of both RNA and DNA synthesis but no significant inhibition of synthesis; at a dose of 5.0 μg/ml, RNA synthesis was 80% inhibited and DNA synthesis was 60% inhibited after 36 hours of incubation with m-AMSA. The difference in the results between in vitro and in vivo SCE studies may be due to possible DNA repair in the in vivo-treated lymphocytes in m-AMSA-free medium in vitro, a process not available to the in vitro-treated cells.

UR - http://www.scopus.com/inward/record.url?scp=0021152862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021152862&partnerID=8YFLogxK

M3 - Article

C2 - 6204755

AN - SCOPUS:0021152862

VL - 68

SP - 989

EP - 997

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7-8

ER -